These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16418506)

  • 1. Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2006 Jan; 98(2):86-7. PubMed ID: 16418506
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative to tamoxifen effective for preventing breast cancer recurrence.
    Mayo Clin Womens Healthsource; 2005 May; 9(5):3. PubMed ID: 15891689
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
    Hargis JB; Nakajima ST
    Cancer Invest; 2006 Mar; 24(2):174-7. PubMed ID: 16537187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].
    Jonat W
    MMW Fortschr Med; 2006 Mar; 148(12):10. PubMed ID: 16625996
    [No Abstract]   [Full Text] [Related]  

  • 8. Anastrozole data show continued delay in relapse, but no clear survival advantage.
    Travis K
    J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
    [No Abstract]   [Full Text] [Related]  

  • 9. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

  • 10. Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies.
    Dixon JM; Bundred N
    Eur J Surg Oncol; 2006 Mar; 32(2):123-5. PubMed ID: 16380226
    [No Abstract]   [Full Text] [Related]  

  • 11. A review of the BIG results: the Breast International Group 1-98 trial analyses.
    Doughty JC
    Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aromatase inhibitors for metastasing breast cancer in postmenopausal women. A survey of a Cochrane review].
    Aziz M; Skougaard K; Kamby C; Nielsen DL
    Ugeskr Laeger; 2008 Jun; 170(25):2248-52. PubMed ID: 18565316
    [No Abstract]   [Full Text] [Related]  

  • 13. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended adjuvant therapy for breast cancer--how much is enough?
    Prowell TM; Stearns V
    J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of brain metastases from breast cancer that responded to anastrozole monotherapy.
    Ito K; Ito T; Okada T; Watanabe T; Gomi K; Kanai T; Mochizuki Y; Amano J
    Breast J; 2009; 15(4):435-7. PubMed ID: 19470131
    [No Abstract]   [Full Text] [Related]  

  • 17. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing extended adjuvant letrozole.
    Gelmon K
    Breast; 2007 Oct; 16(5):446-55. PubMed ID: 17544670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission of macroglobulinemia during anastrozole treatment for breast cancer.
    Chettle C; Baker MA
    N Engl J Med; 2005 Apr; 352(16):1725-6. PubMed ID: 15843681
    [No Abstract]   [Full Text] [Related]  

  • 20. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.